Aristolactam AIIIaCAS# 97399-91-2 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 97399-91-2 | SDF | Download SDF |
| PubChem ID | 10356352 | Appearance | Yellow powder |
| Formula | C16H11NO4 | M.Wt | 281.3 |
| Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| SMILES | COC1=C(C=C2C3=C(C=C4C=CC(=CC4=C31)O)NC2=O)O | ||
| Standard InChIKey | PFXGXKFPTAJYHV-UHFFFAOYSA-N | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Aristolactam AIIIa has anti-tumor activity. 2. Aristolactam AIIIa was identified as a new type of Plk1 inhibitors, targeting the Polo Box domain (PBD). 3. Aristolactam IIIa shows inhibition of platelet aggregation induced by collagen or arachidonic acid. |
| Targets | CDK | MAPK |
Aristolactam AIIIa Dilution Calculator
Aristolactam AIIIa Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.5549 mL | 17.7746 mL | 35.5492 mL | 71.0985 mL | 88.8731 mL |
| 5 mM | 0.711 mL | 3.5549 mL | 7.1098 mL | 14.2197 mL | 17.7746 mL |
| 10 mM | 0.3555 mL | 1.7775 mL | 3.5549 mL | 7.1098 mL | 8.8873 mL |
| 50 mM | 0.0711 mL | 0.3555 mL | 0.711 mL | 1.422 mL | 1.7775 mL |
| 100 mM | 0.0355 mL | 0.1777 mL | 0.3555 mL | 0.711 mL | 0.8887 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Aristolactam AIa
Catalog No.:BCN4854
CAS No.:97399-90-1
- 3alpha-Hydroxytanshinone IIA
Catalog No.:BCN2496
CAS No.:97399-71-8
- 8-Hydroxy-4-cadinen-3-one
Catalog No.:BCN4520
CAS No.:97372-53-7
- Troglitazone
Catalog No.:BCC2016
CAS No.:97322-87-7
- Topiramate
Catalog No.:BCC2314
CAS No.:97240-79-4
- Picfeltarraenin IA
Catalog No.:BCN1041
CAS No.:97230-47-2
- Picfeltarraenin IB
Catalog No.:BCN2845
CAS No.:97230-46-1
- Eriobofuran
Catalog No.:BCN7436
CAS No.:97218-06-9
- Meisoindigo
Catalog No.:BCC5132
CAS No.:97207-47-1
- 3-Ethoxyandrosta-3,5-dien-17-one
Catalog No.:BCC8630
CAS No.:972-46-3
- 6-Epi-8-O-acetylharpagide
Catalog No.:BCN4550
CAS No.:97169-44-3
- 6-Geranylnaringenin
Catalog No.:BCN3001
CAS No.:97126-57-3
- Paniculidine A
Catalog No.:BCN4522
CAS No.:97399-93-4
- Paniculidine B
Catalog No.:BCN4523
CAS No.:97399-94-5
- Paniculidine C
Catalog No.:BCN4524
CAS No.:97399-95-6
- Cynatratoside A
Catalog No.:BCN7087
CAS No.:97399-96-7
- Tanshindiol A
Catalog No.:BCN3123
CAS No.:97411-46-6
- 2',3'-Dehydrosalannol
Catalog No.:BCN4549
CAS No.:97411-50-2
- (-)-Mandelic acid benzyl ester
Catalog No.:BCC8374
CAS No.:97415-09-3
- (-)-5'-DMH-CBD
Catalog No.:BCC5769
CAS No.:97452-63-6
- Cycloart-22-ene-3,25-diol
Catalog No.:BCN4525
CAS No.:97456-49-0
- Tanshindiol B
Catalog No.:BCN3124
CAS No.:97465-70-8
- Tanshindiol C
Catalog No.:BCN3125
CAS No.:97465-71-9
- α-Methyl-5-hydroxytryptamine maleate
Catalog No.:BCC6696
CAS No.:97469-12-0
The natural product Aristolactam AIIIa as a new ligand targeting the polo-box domain of polo-like kinase 1 potently inhibits cancer cell proliferation.[Pubmed:19801998]
Acta Pharmacol Sin. 2009 Oct;30(10):1443-53.
AIM: To search for novel inhibitors of human polo-like kinase 1 (Plk1), which plays important roles in various aspects of mitotic progression and is believed as a promising anti-cancer drug target, and further investigate the potential inhibition mechanism of active compounds against Plk1, thus developing potent anti-tumor lead compounds. METHODS: Surface plasmon resonance (SPR) technology-based assay and enzymatic inhibition assay were used to screen Plk1 inhibitors. Sulphorhodamine B (SRB)-based assay, flow cytometry, confocal microscopy and Western blotting were used to further identify the potent Plk1 inhibitor. To investigate the inhibitory mechanism of the active compound against Plk1, enzymatic inhibition assay, SPR and yeast two-hybrid technology-based assays were used. RESULTS: Aristolactam AIIIa was identified as a new type of Plk1 inhibitors, targeting the Polo Box domain (PBD) which is another efficient tactic for exploring Plk1 inhibitors. Further studies indicated that it could block the proliferations of HeLa, A549, HGC and the HCT-8/V cells (clinical Navelbine-resistant cancer cell), induce mitotic arrest of HeLa cells at G2/M phase with spindle abnormalities and promote apoptosis in HeLa cells. The results from SPR and yeast two-hybrid technology-based assays suggested that it could target both the catalytic domain of Plk1 (CD) and PBD and enhance the CD/PBD interaction. CONCLUSION: Our current work is expected to shed light on the potential anti-tumor mechanism of Aristolactam AIIIa, and this natural product might be possibly used as a lead compound for further developing anti-tumor drugs.
